Amgen reported strong Q4 and full-year 2012 results, highlighting solid performance across its diversified product portfolio and significant capital returns to shareholders through dividends and share repurchases. The company provided optimistic guidance for 2013, expecting to exceed previous revenue and EPS targets ahead of schedule, and emphasized advancements in its pipeline and long-term growth strategies. Management's positive tone and outlook suggest a favorable short-term impact on the stock price.

[1]